Abstract
We report the case of a female never-smoking patient with an epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) who received multiple lines of treatment. When she evolved clinical resistance to first generation EGFR tyrosine kinase inhibitors (TKI), she was treated with a fifth-line combination therapy with cetuximab and vinorelbine. This combination was highly active with a treatment response lasting for 9 months supporting the hypothesis that EGFR monoclonal antibodies in combination with chemotherapy may play a role in reversing EGFR-TKI resistance in EGFR mutation-positive NSCLC.
Keywords:
Acquired resistance; Cetuximab; EGFR mutation; Non-small cell lung cancer (NSCLC).
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Cetuximab
-
Drug Resistance, Neoplasm
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Erlotinib Hydrochloride
-
Female
-
Gefitinib
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Mutation / genetics
-
Neoplasm Staging
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Remission Induction
-
Vinblastine / administration & dosage
-
Vinblastine / adverse effects
-
Vinblastine / analogs & derivatives
-
Vinorelbine
Substances
-
Antibodies, Monoclonal, Humanized
-
Protein Kinase Inhibitors
-
Quinazolines
-
Vinblastine
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
ErbB Receptors
-
Cetuximab
-
Vinorelbine
-
Gefitinib